---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-107367"
form_type: "8-K"
ticker: "RGNX"
cik: "0001590877"
company_name: "REGENXBIO Inc."
filed_at: "2024-09-17T23:59:59+00:00"
generated_at: "2026-05-31T04:15:25.955732+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# REGENXBIO appoints Mitchell Chan as CFO; Vittal Vasista steps down after 15 years

## Summary
- Mitchell Chan appointed EVP, CFO effective Sept. 16, 2024; base salary $490K, 40% bonus target, $3M equity grant (75% options, 25% RSUs).
- Vittal Vasista resigns after 15+ years; separation allowance $500,018 over 3 installments and up to 75% of 2024 targeted bonus.
- Vasista will serve as advisor to CEO through Jan. 3, 2025; unvested equity forfeited after advisory period.
- Chan brings 20 years biopharma finance experience; prior CFO of Viela Bio (led $3B Horizon acquisition) and operating partner at Catalio.

## SEC filing metadata
- accession: 0000950170-24-107367
- form_type: 8-K
- ticker: RGNX
- cik: 0001590877
- company_name: REGENXBIO Inc.
- filed_at: 2024-09-17T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590877/000095017024107367/0000950170-24-107367-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590877/000095017024107367/rgnx-20240916.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-107367
- JSON: https://secwatch.observer/filing/0000950170-24-107367.json
- Plain text: https://secwatch.observer/filing/0000950170-24-107367.txt

## Key facts
- Executive change
  Mitchell Chan was appointed as Executive Vice President, Chief Financial Officer and Principal Accounting Officer at REGENXBIO Inc..
  - Action: appointed
  - Role: Executive Vice President, Chief Financial Officer and Principal Accounting Officer
  source text: On September 16, 2024, the board of directors (the “Board” of REGENXBIO Inc. (the “Company”) appointed Mitchell Chan as Executive Vice President, Chief Financial Officer and Principal Accounting Officer, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1590877/000095017024107367/0000950170-24-107367-index.htm
- Executive change
  Vittal Vasista resigned as Executive Vice President, Chief Financial Officer and Principal Accounting Officer at REGENXBIO Inc..
  - Action: resigned
  - Role: Executive Vice President, Chief Financial Officer and Principal Accounting Officer
  source text: the Board accepted the resignation of Vittal Vasista from his position as Executive Vice President, Chief Financial Officer and Principal Accounting Officer, effective as of September 16, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1590877/000095017024107367/0000950170-24-107367-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.